Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.

Giovane, Richard A; Rezai, Shadi; Cleland, Ellen; Henderson, Cassandra E

Giovane, Richard A; Rezai, Shadi; Cleland, Ellen; Henderson, Cassandra E.

Giovane RA; Department of Family Medicine, Regional Medical Center of Central Alabama, Greenville, Alabama, USA.
Rezai S; Department of OB/GYN, Valley Community Healthcare, North Hollywood, California, USA.
Cleland E; Department of Family Medicine, University of Alabama, Tuscaloosa, Alabama, USA.
Henderson CE; Garden OB/GYN, Mercy Medical Center, New York, New York, USA.

Rev Med Virol ; 30(5): e2136, 2020 09.

Article in English | MEDLINE | ID: covidwho-636609

ABSTRACT

ABSTRACT

SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.

Subject(s)

Antiviral Agents/therapeutic use; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Coronavirus Infections/epidemiology; Host-Pathogen Interactions/drug effects; Pandemics; Pneumonia, Viral/drug therapy; Pneumonia, Viral/epidemiology; Adenosine Monophosphate/analogs & derivatives; Adenosine Monophosphate/therapeutic use; Alanine/analogs & derivatives; Alanine/therapeutic use; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized/therapeutic use; Betacoronavirus/immunology; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/immunology; Coronavirus Infections/virology; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate/analogs & derivatives; Gabexate/therapeutic use; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions/genetics; Host-Pathogen Interactions/immunology; Humans; Hydroxychloroquine/therapeutic use; Indoles/therapeutic use; Lopinavir/therapeutic use; Peptidyl-Dipeptidase A/genetics; Peptidyl-Dipeptidase A/immunology; Pneumonia, Viral/immunology; Pneumonia, Viral/virology; Ritonavir/therapeutic use; SARS-CoV-2; Spike Glycoprotein, Coronavirus/antagonists & inhibitors; Spike Glycoprotein, Coronavirus/genetics; Spike Glycoprotein, Coronavirus/immunology

Keywords

2019-nCoV; COVID-19; Lopinavir/Ritonavir; RNA-dependent RNA polymerase inhibitors; Remdesivir; SARS CoV-2; SARS coronavirus (SARS-CoV); Umifenovir; acetazolamide; acute respiratory distress syndrome (ARDS); autoimmune; camostat mesylate; chloroquine; high altitude pulmonary edema (HAPE); hydroxychloroquine; novel coronavirus 2019; pandemic; severe acute respiratory syndrome (SARS)

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Host-Pathogen Interactions / Pandemics / Betacoronavirus Type of study: Observational study / Prognostic study Language: English Journal: Rev Med Virol Journal subject: Virology Year: 2020 Document Type: Article Affiliation country: Rmv.2136

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google